Valium 10 mg

Product Beschrijving

1. Classification and Chemical Overview

Valium 10mg is a well-established branded and generic oral pharmaceutical preparation of diazepam, originally developed and synthesized by Hoffmann-La Roche. Chemically designated as $7\text{-chloro-1-methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one}$, diazepam is the prototypical member of the classical 1,4-benzodiazepine chemical class. Its molecular architecture consists of a fused benzene and seven-membered diazepine heterocycle substituted with an electron-withdrawing chlorine atom at the carbon-7 position, a methyl group on the nitrogen at the 1-position, a carbonyl oxygen at the 2-position, and an unsubstituted phenyl ring at the carbon-5 position. Its empirical molecular formula is $\text{C}_{16}\text{H}_{13}\text{ClN}_2\text{O}$, with an average molecular mass of $284.74\text{ g/mol}$.

Standard solid-dose formulations of Valium 10mg present as round, light-blue film-coated or compressed tablets (characteristically featuring the iconic “V” cutout or score lines on innovator presentations, or flat/bisected faces on generic multi-source preparations). In addition to $10\text{ mg}$ of pure diazepam base, conventional formulations incorporate non-active pharmaceutical excipients including lactose monohydrate, maize starch, pregelatinized starch, magnesium stearate, and authorized colorants (such as indigo carmine / E132 or FD&C Blue No. 1).

Within the United Kingdom regulatory framework, diazepam is classified as a Prescription Only Medicine (POM) governed by the Human Medicines Regulations 2012. Under the Misuse of Drugs Act 1971 and the Misuse of Drugs Regulations 2001, diazepam is scheduled as a Class C, Schedule 4 (Part 1 / CD Benz POM) controlled substance. It is authorized by the Medicines and Healthcare products Regulatory Agency (MHRA), fully listed on the British National Formulary (BNF), and reimbursable under standard NHS primary care prescription tariffs (FP10). Due to extensive illicit diversion, grey-market internet supply, and recreational polysubstance misuse, counterfeit “Valium 10mg” tablets (often called “street blues” or “D10s”) represent a major public health hazard; forensic analyses frequently reveal that black-market blue tablets contain zero diazepam, instead harboring potent illicit designer benzodiazepines (e.g., bromazolam, flubromazepam) or synthetic opioids (such as nitazenes).

2. Mechanism of Action and Pharmacodynamics

The pharmacodynamic profile of diazepam is characterized by classic, non-selective positive allosteric modulation of inhibitory neurotransmission across the central nervous system (CNS):

• Positive Allosteric Modulation of the $GABA_A$ Receptor: Diazepam binds stereospecifically to the high-affinity benzodiazepine allosteric binding pocket located at the interface between the $\alpha$ ($\alpha_1$, $\alpha_2$, $\alpha_3$, or $\alpha_5$) and $\gamma_2$ subunits of the pentameric $\gamma\text{-aminobutyric acid type A}$ ($GABA_A$) ligand-gated chloride ion channel complex.

• Chloride Conductance and Hyperpolarization: In the absence of endogenous $\text{GABA}$, diazepam exhibits no intrinsic agonism (it lacks direct $\text{GABA}$-mimetic properties at clinical concentrations). When endogenous $\text{GABA}$ binds to its orthosteric sites, diazepam induces a positive conformational shift that increases the frequency of channel opening bursts (in contrast to barbiturates, which increase channel open duration). The resulting influx of extracellular chloride ions ($Cl^-$) down an electrochemical gradient causes hyperpolarization of the postsynaptic neuronal membrane, stabilizing resting membrane potentials below the threshold needed to generate action potentials.

• Subunit-Mediated Clinical Pharmacodynamics:

  • $\alpha_1$ Subunit Interactions: Predominant in the cerebral cortex, thalamus, and cerebellum; mediates non-specific sedation, hypnotic efficacy, anterograde amnesia, and broad anticonvulsant activity.

  • $\alpha_2$ en $\alpha_3$ Subunit Interactions: Concentrated within the limbic networks (amygdala, hippocampus) and spinal motor neurons; responsible for anxiolysis, anti-panic effects, and central skeletal muscle relaxation (via spinal reflex depression).

  • $\alpha_5$ Subunit Interactions: Localized primarily in the hippocampus; mediates cognitive fragmentation, spatial learning impairment, and memory consolidation deficits.

• Comparative Pharmacodynamics: Diazepam is considered the standard reference benchmark for benzodiazepine comparisons ($10\text{ mg}$ oral diazepam serves as the baseline equivalency standard). While possessing lower absolute receptor affinity than high-potency agents (such as clonazepam or alprazolam), its pronounced lipophilicity confers rapid central nervous system penetration, resulting in immediate clinical effects followed by prolonged actions sustained by an array of biologically active metabolites.

3. Approved UK Clinical Indications and Therapeutic Scope

Diazepam holds broad, multi-system licensed indications in the United Kingdom under BNF and MHRA prescribing parameters:

• Short-Term Management of Severe Anxiety: Indicated for severe, disabling, or incapacitating anxiety states (with or without insomnia) refractory to conservative measures. Prescribing guidelines strictly limit treatment to 2 to 4 weeks maximum (including gradual dose tapering) to mitigate rapid physical and psychological dependence.

• Symptomatic Management of Acute Alcohol Withdrawal Syndrome: First-line agent for mitigating autonomic hyperarousal, tremor, agitation, alcohol withdrawal seizures, and delirium tremens, typically administered via structured symptom-triggered protocols (e.g., CIWA-Ar).

• Control of Muscle Spasm and Spasticity: Adjunctive treatment for painful skeletal muscle spasms secondary to local trauma, inflammation, or upper motor neuron neurological spasticity (e.g., cerebral palsy, paraplegia, stiff person syndrome).

• Management of Seizure Disorders and Status Epilepticus: Used as an anticonvulsant adjunct for managing recurring epileptic seizures; parenteral and rectal formulations serve as classical first-line emergency rescue therapies for terminating acute prolonged epileptic seizures and status epilepticus.

• Pre-operative and Dental Sedation: Used for pre-medication prior to surgical interventions, minor endoscopic procedures, or dental interventions to produce sedation, reduce anxiety, and induce anterograde amnesia.

The National Institute for Health and Care Excellence (NICE) strictly delineates benzodiazepine use across multiple guidelines (e.g., CG113 for Generalized Anxiety Disorder and Panic Disorder, CG115 for Alcohol-use Disorders). NICE advises against long-term prescribing for anxiety, positioning cognitive behavioral therapy (CBT), SSRIs, and SNRIs as first-line maintenance interventions. Long-term diazepam prescribing is discouraged due to tolerance, cognitive blunting, falls risk in the elderly, and withdrawal difficulties.

In non-clinical and illicit environments, Valium 10mg is extensively misused:

• Mitigating unpleasant post-stimulant dysphoria (“comedowns” following cocaine, amfetamines, or MDMA).

• Self-directed, uncontrolled alcohol and benzodiazepine withdrawal self-management.

• Recreational polydrug intoxication (co-ingested with opioids or alcohol to potentiate euphoric and sedative detachment).

4. Pharmacokinetic Profile and Metabolic Fate

The pharmacokinetic profile of diazepam is defined by rapid gastrointestinal absorption, high lipophilicity, biphasic elimination, and extensive hepatic biotransformation yielding potent, long-lived active metabolites:

• Absorption: Following oral administration, diazepam is rapidly and almost completely absorbed across the gastrointestinal tract. In a fasting state, peak plasma concentrations ($C_{max}$) are reached between 30 and 90 minutes (median $T_{max} \approx 60\text{ minutes}$). Absolute oral bioavailability is high, ranging from $75\text{ to }100\%$. Ingestion alongside large, high-fat meals blunts and delays the peak systemic absorption by up to 1.5 to 2 hours.

• Distribution: Diazepam is highly lipophilic ($\text{LogP} \approx 2.8$), allowing it to cross the blood-brain barrier rapidly within minutes to produce prompt sedation. However, this same lipophilicity drives rapid redistribution from the central nervous system into peripheral adipose tissue and skeletal muscle (distribution phase half-life: $1\text{ to }3\text{ hours}$). Consequently, the acute clinical sedative effect of a single dose may diminish after a few hours despite substantial amounts of the drug remaining in the body. Diazepam possesses a steady-state volume of distribution ($V_{ss}$) of $0.8\text{ to }1.5\text{ L/kg}$ (which expands significantly in the elderly and obese). It is extensively bound to human plasma proteins ($98\text{ to }99\%$ bound), primarily human serum albumin.

• Biotransformation: Diazepam undergoes complex, multi-step hepatic biotransformation mediated by cytochrome P450 enzymes (predominantly CYP2C19 en CYP3A4), generating an active metabolic cascade:

  • N-Demethylation (CYP2C19, CYP3A4): Converts diazepam into its major primary active metabolite, $N\text{-desmethyldiazepam}$ (nordiazepam). Nordiazepam possesses full biological activity at $GABA_A$ receptors and exhibits an extraordinarily prolonged elimination half-life ($t_{1/2} \approx 40\text{ to }100+\text{ hours}$), leading to marked clinical accumulation during repeated daily dosing.

  • Hydroxylation (CYP3A4): Hydroxylates diazepam at the carbon-3 position to form temazepam (active; $t_{1/2} \approx 8\text{ to }15\text{ hours}$).

  • Secondary Oxidation: Both nordiazepam and temazepam are further metabolized into oxazepam (active; $t_{1/2} \approx 4\text{ to }10\text{ hours}$).

  • Phase II Inactivation: Oxazepam and other hydroxylated derivatives undergo rapid glucuronidation via UDP-glucuronosyltransferases (UGTs) to yield inactive, water-soluble glucuronide conjugates.

• Elimination: Systemic elimination is predominantly renal, with approximately $70\text{ to }80\%$ of an administered dose excreted in the urine as polar glucuronide conjugates, and approximately $10\%$ eliminated via the biliary-faecal route. Less than $1\%$ is excreted unchanged. The terminal elimination half-life ($t_{1/2}$) of parent diazepam in healthy adults is 20 to 50 hours. In elderly patients, neonates, or individuals with severe hepatic cirrhosis, the half-life of parent diazepam can exceed 100 hours, with its active metabolite nordiazepam persisting for weeks.

5. Physiological Effects and Adverse Event Spectrum

The primary physiological action in clinical use is generalized, concentration-dependent reduction of central autonomic, somatic, and cognitive arousal. However, widespread $GABA_A$ positive modulation produces an extensive adverse event spectrum:

• Neuropsychiatric and Cognitive Impairments (Very Common, $\ge 1/10$):

  • Daytime somnolence, excessive sedation, fatigue, and muscular weakness.

  • Anterograde amnesia: transient impairment in encoding new declarative memories, contributing to blackouts at high therapeutic or recreational doses.

  • Psychomotor retardation, cognitive blunting, and prolonged reaction times.

  • Paradoxical reactions: unprovoked behavioral disinhibition, agitation, irritability, aggression, rage, nightmares, and transient hallucinations (seen more frequently in elderly, pediatric, or psychiatric populations).

• Neuromuscular and Sensorimotor Disruptions (Common, $1/100$ to $<1/10$):

  • Cerebellar ataxia, loss of motor coordination, unsteady gait, and dysarthria (slurred speech), substantially elevating the risk of mechanical falls and hip fractures in vulnerable elderly cohorts.

  • Vertigo, lightheadedness, and headache.

• Severe, Emergent and Life-Threatening Hazards (Rare to Polysubstance Toxicity):

  • Synergistic Respiratory Depression and Fatal Hypoxia: In isolation, oral diazepam overdose rarely results in fatal central apnea in healthy individuals; however, co-administration with other central nervous system depressants (especially opioids, alcohol, or sedating antihistamines) is frequently fatal. Synergistic depression of brainstem medullary respiratory centers induces severe central hypoventilation, hypercapnic respiratory failure, deep coma, and fatal asphyxiation.

  • Tolerance, Physical Dependence, and Severe Withdrawal Crisis: Regular administration exceeding 2 to 4 weeks induces down-regulation and conformational uncoupling of $GABA_A$ receptors, paired with secondary up-regulation of excitatory glutamatergic (NMDA) transmission. Abrupt cessation in dependent individuals precipitates a potentially life-threatening withdrawal syndrome:

    • Severe rebound anxiety, agoraphobia, panic attacks, and intractable insomnia.

    • Autonomic hyperactivity: sinus tachycardia, malignant hypertension, profuse diaphoresis, and fine tremors.

    • Depersonalization, derealization, perceptual hypersensitivity (photophobia, hyperacusis), and confusion.

    • Severe Complications: Delirium tremens, hallucinations (auditory, visual, tactile), malignant hyperthermia, and status epilepticus (prolonged or recurring grand mal convulsions), which can cause permanent hypoxic brain damage, rhabdomyolysis, and death if not emergently treated.

  • Pulmonary Aspiration: Profound drug-induced stupor accompanied by vomiting carries a high risk of chemical pneumonitis and fatal airway obstruction due to blunted protective pharyngeal reflexes.

6. Contraindications, Drug Interactions, and Clinical Precautions

Prescribing, administering, or evaluating individuals exposed to Valium 10mg requires strict adherence to pharmacological contraindications, drug-interaction screening, and harm-minimisation standards:

• Contraindications:

  • Severe Respiratory Depression: Absolute contraindication in acute respiratory failure, severe chronic obstructive pulmonary disease (COPD), or decompensated respiratory depression.

  • Myasthenia Gravis: Absolute contraindication; intrinsic skeletal muscle-relaxant actions can precipitate fatal respiratory muscle paralysis.

  • Sleep Apnea Syndrome: Contraindicated due to the risk of exacerbating severe nocturnal hypoxia and prolonged central obstructive apneas.

  • Severe Hepatic Impairment: Absolute contraindication in advanced hepatic cirrhosis and acute liver failure due to impaired oxidative metabolism, massive drug accumulation, and the precipitating risk of hepatic encephalopathy.

  • Acute Narrow-Angle Glaucoma: Contraindicated (anticholinergic-like pupillary fluctuations).

  • Pregnancy and Lactation: Contraindicated unless clinically essential; crosses the placenta, risks fetal developmental disruption, causes neonatal “floppy infant syndrome” (hypothermia, hypotonia, respiratory distress), and precipitates neonatal withdrawal; concentrates in maternal breast milk.

• Drug Interactions:

  • Opioids (e.g., Morphine, Methadone, Buprenorphine, Oxycodone, Fentanyl): Major synergistic hazard; profound, potentially fatal depression of the medullary ventilatory drive. Co-prescribing requires rigorous clinical justification, minimum dosing, and close monitoring.

  • Ethanol (Alcohol): Synergistically amplifies $GABA_A$ receptor chloride conductance, producing rapid loss of consciousness, profound amnesia, fatal respiratory arrest, and elevated trauma risks.

  • Cytochrome P450 Inhibitors (e.g., CYP2C19 inhibitors like Omeprazole, Cimetidine, Fluconazole; CYP3A4 inhibitors like Ketoconazole, Erythromycin, Clarithromycin, Ritonavir): Markedly reduces the metabolic clearance of diazepam and nordiazepam, substantially prolonging elimination half-lives and predisposing to profound cumulative toxicity.

  • CYP Inducers (e.g., Rifampicin, Carbamazepine, Phenytoin, St John’s Wort): Accelerates hepatic clearance, dropping systemic diazepam levels and potentially precipitating breakthrough seizures or acute withdrawal in dependent individuals.

  • Centrally Acting Muscle Relaxants, Antipsychotics, and Sedating Antihistamines: Additive central depression and impaired psychomotor capabilities.

• Clinical Precautions and Harm Minimisation:

  • Acute Overdose Management (“Red Flags”): Patients presenting to NHS emergency departments (999/A&E) with profound stupor, unresponsiveness, bradypnea, or airway compromise require immediate emergency care:

    • Airway and Ventilatory Support: Maintain a patent airway, place the patient in the lateral recovery position, provide supplemental oxygen, and initiate bag-valve-mask or mechanical ventilation if hypoventilation is present.

    • Judicious Use of Flumazenil: The specific $GABA_A$ antagonist flumazenil ($0.2\text{ mg}$ IV slowly, titrated up to $1.0\text{ mg}$) is available in hospital settings, but must be used with extreme caution. It is strictly contraindicated in patients with mixed overdoses (especially involving pro-convulsant drugs like tricyclic antidepressants) or in individuals with chronic benzodiazepine tolerance, as acute receptor displacement can precipitate intractable, life-threatening status epilepticus. Its clinical utility is largely restricted to reversing acute pediatric accidental ingestion or isolated, non-dependent iatrogenic sedation.

  • Structured Discontinuation and Detoxification Protocols: Chronic diazepam use must never be halted abruptly. Tapering schedules should be individualized, reducing doses gradually (e.g., reducing by $1\text{ to }2\text{ mg}$ every 1 to 2 weeks, or by $10\%$ every fortnight) under structured medical supervision (such as NHS community addiction or primary care reduction plans). Because of its long half-life and active metabolites, diazepam is paradoxically the gold-standard substitution agent used to taper patients off shorter-acting benzodiazepines (e.g., alprazolam, lorazepam) and novel designer analogues.

  • Driving and Legal Regulations: Under Section 5A of the Road Traffic Act 1988, it is a criminal offence to drive with specified controlled drugs in the blood above statutory limits. The UK legal limit for diazepam is $550\text{ mcg/L}$. While a statutory medical defense exists for patients taking medications strictly as prescribed, patients must be warned that driving while their driving skills are impaired remains an offence under Section 4 of the Act.

  • Counterfeit Sourcing Warnings: Healthcare professionals encountering individuals taking black-market “Valium 10mg” or blue tablets acquired online must clearly communicate that illicit supplies routinely contain novel synthetic designer benzodiazepines (e.g., bromazolam) or synthetic nitazene opioids, carrying critical, unpredictable risks of fatal poisoning.

Aanvullende Informatie